Street Calls of the Week
Vericel Corp’s stock reached a 52-week low, closing at 33.04 USD, significantly below its 52-week high of 63 USD. This marks a significant downturn for the company, as its stock has experienced a 24.45% decrease over the past year. According to InvestingPro data, the company maintains strong fundamentals with a current ratio of 4.97 and revenue growth of 16.13% in the last twelve months. The biopharmaceutical company, which focuses on advanced cell therapies for the sports medicine and severe burn care markets, has faced challenges that have impacted its stock performance. This recent low highlights the volatility within the sector and the pressures Vericel is currently navigating. Analysts remain optimistic, with price targets ranging from 45 to 62 USD. Investors will be closely monitoring the company’s next moves as it attempts to recover from this slump. InvestingPro subscribers have access to 12 additional investment tips and comprehensive analysis for VCEL.
In other recent news, Vericel Corporation reported its second-quarter 2025 earnings, showing a narrowed net loss and a rise in revenue. The company posted an earnings per share loss of $0.01, which was better than the anticipated loss of $0.03. However, revenue slightly fell short of expectations, reaching $63.24 million compared to the forecasted $64.61 million. Canaccord Genuity adjusted its price target for Vericel to $58.00 from $61.00, while maintaining a Buy rating, citing mixed performance in the latest quarterly results. The MACI product line missed revenue targets, whereas Epicel showed lower-than-expected revenue despite a record number of biopsies. TD Cowen reiterated a Buy rating with a $55.00 price target, expressing confidence in the growth potential of Vericel’s MACI Arthro product. The MACI Arthro, having received regulatory approval in the third quarter of 2024, is currently being launched across the United States. These developments reflect ongoing changes and expectations within Vericel’s business landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.